Duke Street Bio disclosed development of new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors, describing them as potentially useful for cancer treatment. The update frames the program as part of the company’s ongoing small-molecule strategy targeting DNA damage response pathways associated with PARP dependence in tumors.